Compare MOGU & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOGU | ASBP |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 18.9M |
| IPO Year | 2018 | N/A |
| Metric | MOGU | ASBP |
|---|---|---|
| Price | $2.48 | $0.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 17.4M |
| Earning Date | 11-21-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,462,964.00 | $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.83 | $0.07 |
| 52 Week High | $8.10 | $15.80 |
| Indicator | MOGU | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 43.78 |
| Support Level | $2.39 | $0.09 |
| Resistance Level | $2.71 | $0.10 |
| Average True Range (ATR) | 0.13 | 0.01 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 19.57 | 76.36 |
MOGU Inc is an online service provider in China, operating a KOL-driven online fashion and lifestyle platform, Mogujie, and providing customized online branding solutions to businesses. The company, on its platform, provides content related to fashion and lifestyle guides in various multimedia formats, which include Live Video Broadcasts, Short-form Videos, Photography, and an Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology, and other relevant services to merchants and users, as well as technology services to brand owners.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.